BACKGROUND: Comorbidities complicate clinicians' efforts to manage major depressive disorder (MDD). Pre-existing conditions and drug-drug interactions (DDI) may limit the array of safe ph...
Background: Antipsychotics with reduced dosing frequency may improve adherence and clinical outcomes for patients with schizophrenia. This study compared adherence, persistence, healthcar...
BACKGROUND: To understand heterogeneity among the population with major depressive disorder (MDD) and suicidal ideation (SI) or attempt (SA) (MDD+SI/SA), clusters were identified through ...
BACKGROUND: Esketamine nasal spray was approved for adults with treatment-resistant depression on 03/05/2019. Real-world data on patients initiated on esketamine is limited.
METHODS: Adu...
Background: Schizophrenia carries a substantial economic burden to healthcare systems and payers. This study aims to update the prevalence, incidence and economic burden of schizophrenia ...
Background: Medication non-adherence is common for patients with schizophrenia. Decreasing dosing frequency of patients adequately treated with once-monthly paliperidone palmitate (PP1M) ...
Background: Among patients with major depressive disorder (MDD), those with treatment-resistant depression (TRD) have a higher economic burden. However, healthcare resource utilization (H...